Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis

Arthritis Rheum. 2006 Feb 15;55(1):150-3. doi: 10.1002/art.21707.
No abstract available

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antirheumatic Agents / administration & dosage*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Carotid Artery Diseases / complications
  • Carotid Artery Diseases / drug therapy*
  • Carotid Artery Diseases / immunology
  • Disease Progression
  • Drug Resistance
  • Female
  • Humans
  • Infliximab
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Methotrexate